|
|
|
|
Direct Cost |
Indirect Cost |
|
1F30AI176796-01A1 |
Harnessing Amide Linkers for Antitubercular Drug Development |
RUTGERS BIOMEDICAL AND HEALTH SCIENCES |
NIAID |
$43,128 |
|
$43,128 |
1F31AI176806-01A1 |
Host-pathogen interactions and carbon processing in glycerol kinase deficient Mycobacterium tuberculosis |
RUTGERS BIOMEDICAL AND HEALTH SCIENCES |
NIAID |
$43,398 |
|
$43,398 |
1F31ES036099-01 |
Per- and polyfluoroalkyl substances (PFAS) occurrence and associations with dyslipidemia among community-based U.S. volunteer firefighters |
RUTGERS BIOMEDICAL AND HEALTH SCIENCES |
NIEHS |
$45,052 |
|
$45,052 |
1F31NS135951-01 |
Negative regulatory mechanism of mechanically activated PIEZO2 channels by TMEM120A/TACAN |
RUTGERS BIOMEDICAL AND HEALTH SCIENCES |
NINDS |
$32,276 |
|
$32,276 |
1K01CA281062-01A1 |
A new generation of misleading tobacco marketing: Assessing the evolution of misleading combustible tobacco marketing features and detrimental implications for vulnerable youth and young adults |
RUTGERS BIOMEDICAL AND HEALTH SCIENCES |
NCI |
$205,418 |
$16,433 |
$221,851 |
1K01DA058168-01A1 |
Molecular mechanisms of incubation of methamphetamine craving |
RUTGERS BIOMEDICAL AND HEALTH SCIENCES |
NIDA |
$195,566 |
$15,645 |
$211,211 |
1K01ES035734-01 |
Exposure to Per- and Polyfluoroalkyl Substances and Prostate Cancer: Opportunities for Prevention and Early Detection |
RUTGERS BIOMEDICAL AND HEALTH SCIENCES |
NIEHS |
$171,215 |
$13,697 |
$184,912 |
1K08CA283268-01A1 |
Evaluating, Preparing, and Responding to Care Disruptions and Health Outcomes Among Patients with Breast Cancer Following Severe Storms |
RUTGERS BIOMEDICAL AND HEALTH SCIENCES |
NCI |
$230,757 |
$18,461 |
$249,218 |
1K23DA058808-01A1 |
Neural, genetic, and environmental indicators of treatment outcomes for adolescent substance use |
RUTGERS BIOMEDICAL AND HEALTH SCIENCES |
NIDA |
$160,652 |
$12,852 |
$173,504 |
1K24NR021198-01 |
Mentored patient-oriented research that applies a social determinants of health lens to promote optimal developmental and behavioral health in primary care |
RUTGERS BIOMEDICAL AND HEALTH SCIENCES |
NINR |
$160,262 |
$12,821 |
$173,083 |
1K99DA057372-01A1 |
Scaling-up Medication for Opioid Use Disorder in Residential Treatment Settings |
RUTGERS BIOMEDICAL AND HEALTH SCIENCES |
NIDA |
$201,740 |
$16,139 |
$217,879 |
1K99DA058711-01A1 |
Using Mobile Technology to Examine Mechanisms Linking Sleep and Smoking Cessation |
RUTGERS BIOMEDICAL AND HEALTH SCIENCES |
NIDA |
$195,566 |
$15,645 |
$211,211 |
1R01AI175555-01A1 |
Imaging signatures of early tuberculosis |
RUTGERS BIOMEDICAL AND HEALTH SCIENCES |
NIAID |
$473,846 |
$142,904 |
$616,750 |
1R01AI179926-01 |
Development of 2C inhibitors as broad-spectrum enterovirus antivirals |
RUTGERS BIOMEDICAL AND HEALTH SCIENCES |
NIAID |
$494,983 |
$186,194 |
$681,177 |
1R01AI179961-01 |
Nanoreactor beads for POC TB resistance testing |
RUTGERS BIOMEDICAL AND HEALTH SCIENCES |
NIAID |
$464,399 |
$168,149 |
$632,548 |
1R01AI182257-01 |
Point of care detection of fluroquinolone, bedaquiline and linezolid resistant Mycobacterium tuberculosis for rapid treatment decisions. |
RUTGERS BIOMEDICAL AND HEALTH SCIENCES |
NIAID |
$575,972 |
$142,484 |
$718,456 |
1R01CA285513-01 |
The role of pyruvate kinase as a therapeutic target in T-ALL |
RUTGERS BIOMEDICAL AND HEALTH SCIENCES |
NCI |
$228,750 |
$130,388 |
$359,138 |
1R01CA285774-01 |
Elucidation of hypoxia-induced metastatic reprogramming through the regulation of KDM8 function in pancreatic cancer |
RUTGERS BIOMEDICAL AND HEALTH SCIENCES |
NCI |
$314,483 |
$165,940 |
$480,423 |
1R01DA058664-01A1 |
Improving Outcomes and Equity for Released Prisoners with SUD: Trajectories of Participation in Pre-Release and Post-Release MOUD, Peer Navigation, and Outcomes |
RUTGERS BIOMEDICAL AND HEALTH SCIENCES |
NIDA |
$449,999 |
$256,499 |
$706,498 |
1R01DK135857-01A1 |
Orexin glucose-inhibited neurons and hypoglycemia unawareness |
RUTGERS BIOMEDICAL AND HEALTH SCIENCES |
NIDDK |
$394,341 |
$192,190 |
$586,531 |